Form 4: Agios CEO Brian Goff Reports Equity Transactions

Agios Pharmaceuticals CEO Brian Goff reported the acquisition of new equity awards and the sale of shares to cover tax obligations related to vested performance share units.

Summary

• Brian Goff, CEO and Director of Agios Pharmaceuticals, Inc. (AGIO), reported multiple equity transactions on March 1 and March 2, 2026.
• Transactions included the vesting of previously granted restricted stock units (RSUs) and the sale of shares to cover tax withholding obligations.
• Goff acquired a total of 39,500 common shares through the vesting of RSUs (8,500, 18,000, and 13,000 shares respectively) on March 2, 2026.
• He sold a total of 18,055 common shares at a price of $28.96 per share to satisfy tax withholding obligations related to the RSU vestings. These sales were pre-planned under Rule 10b5-1(c) plans.
• Goff was granted 48,000 new restricted stock units (RSUs) on March 1, 2026, which will vest in three equal annual installments starting March 1, 2027.
• He was also granted 174,000 new stock options on March 1, 2026, with an exercise price of $30.23 and an expiration date of March 1, 2036. These options will vest 25% on March 1, 2027, with the remainder vesting monthly over 36 months.
• Following these transactions, Goff beneficially owns 164,548 shares of common stock, 48,000 restricted stock units, and 174,000 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the significant new equity grants (RSUs and stock options) to the CEO, which align his interests with long-term company performance, despite the routine tax-related sales.

Positives

• Grant of 48,000 new restricted stock units (RSUs) to the CEO on March 1, 2026.
• Grant of 174,000 new stock options to the CEO on March 1, 2026, indicating continued long-term incentive alignment.
• Vesting of 39,500 common shares from previously granted restricted stock units, increasing direct share ownership before tax sales.

Negatives

• Sale of 18,055 common shares at $28.96 per share to cover tax withholding obligations, reducing direct share ownership.

Future Outlook

The filing details future vesting schedules for newly granted restricted stock units and stock options, indicating a long-term incentive structure for the CEO. The 48,000 new RSUs will vest in three equal annual installments starting March 1, 2027, and the 174,000 new stock options will vest 25% on March 1, 2027, with the remainder vesting monthly over 36 months.

Industry Context

StockSavvy.ai notes that the grant of new equity awards to a Chief Executive Officer is a standard practice in the biotechnology and pharmaceutical industry, aligning executive incentives with long-term shareholder value. The use of Rule 10b5-1 plans for tax-related sales is also a common and transparent mechanism for insiders to manage their equity holdings.

Comparison to Industry Standards

• StockSavvy.ai observes that the equity compensation structure, involving both restricted stock units and stock options with multi-year vesting schedules, is consistent with common practices among peer biotechnology companies of similar market capitalization.
• For instance, companies like Vertex Pharmaceuticals (VRTX) and Biogen (BIIB) frequently utilize similar long-term incentive plans for their executive leadership, aiming to retain talent and incentivize performance over several years.
• The specific grant sizes and vesting terms are within the typical range for a CEO of a company like Agios, which is actively involved in clinical development and commercialization of therapies.

Stakeholder Impact

• Shareholders: The grants of new equity awards to the CEO align his long-term incentives with shareholder value creation. The tax-related sales are routine and do not indicate a change in management's confidence.
• Employees: The compensation structure for the CEO may reflect broader compensation strategies within the company, potentially influencing employee morale and retention.

Next Steps

• The 48,000 new restricted stock units will begin vesting in three equal annual installments starting March 1, 2027.
• The 174,000 new stock options will vest 25% on March 1, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Key Dates

Recommendation

The filing details routine insider transactions, including new equity grants and tax-related sales under a pre-arranged plan. These actions are standard for executive compensation and tax management and do not provide new fundamental information to warrant a change in investment thesis. The new grants reinforce long-term alignment, but the sales are expected. Therefore, a 'hold' recommendation is appropriate as this filing does not present a significant catalyst for a 'buy' or 'sell' decision.

Keywords

Agios Pharmaceuticals, AGIO, Brian Goff, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, CEO, Director, Rule 10b5-1, Tax Withholding